Previous close | 93.64 |
Open | 93.80 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 93.64 - 93.64 |
52-week range | 90.12 - 109.00 |
Volume | |
Avg. volume | 43,259 |
Market cap | 191.398B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 22.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.76 (4.02%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.